DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06410352

RecruitingPhase 4

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Effectiveness of Pharmacologic, Surgical, and Dietetic Weight Loss Methods on Lifespan in Patients With Metabolic Syndrome: a Comparative Clinical Trial

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

220

estimated

Study population

Hypertension, Metabolic syndrome, Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥27

Primary endpoints

•Body weight, absolute change (kg)•BMI, change•Total fat mass

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06410352
Org study IDAP23488544

Timeline

Milestones

Study start2024-03-01actual
Study first posted2024-05-13actual
Primary completion2025-09-30actual
Last update posted2025-11-26actual
Study completion2026-07-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

HypertensionMetabolic syndromeObesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age35 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•written informed consent;
•T2D≥3-year with glucose lowering therapy including insulin;
•35-55 years old;
•BMI≥27 kg/m2 for both sex, for Asian ethnicity;
•ongoing treatment with antihypertensive treatment;
•weight loss 15-20% at baseline and dynamic follow-up up to 24 weeks.

Exclusion criteria

•T1D;
•<34 age >56 years old;
•unstable cardiac disorders (New York Heart Association class IV heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease, or severe uncontrolled hypertension);
•glomerular filtration rate <30 mL/min and/or dialysis within 14 days before screening; • malignancy within the past 5 years;
•gestation or lactation;
•hereditary diseases;
•known hypersensitivity to any of the test substances.

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Cardiometabolic biomarkers
4
Glycemic / diabetes
3

Weight & body composition

4 endpoints
Primary/protocol endpoint

Weight

Time frame:Baseline, 24 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Primary/protocol endpoint

Body mass index

Time frame:Baseline, 24 weeks

BMI, change

change from baseline, improvement

Primary/protocol endpoint

Fat mass

Time frame:Baseline, 24 weeks

Total fat mass

change from baseline, improvement

Primary/protocol endpoint

Fat free mass

Time frame:Baseline, 24 weeks

Lean mass

change from baseline, improvement

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

blood insulin level

Time frame:Baseline, 24 weeks

change from baseline, improvement

Primary/protocol endpoint

Fasting blood glucose

Time frame:Baseline, 24 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

HbA1c

Time frame:Baseline, 24 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

4 endpoints
Primary/protocol endpoint

systolic/diastolic Blood presure

Time frame:Baseline, 24 weeks

change from baseline, improvement

Secondary/protocol endpoint

Total cholesterol

Time frame:Baseline, 24 weeks

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Triglycerides

Time frame:Baseline, 24 weeks

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

High-density lipoprotein

Time frame:Baseline, 24 weeks

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.